Literature DB >> 8341214

Increased risk of cardiac dysfunction after anthracyclines in girls.

J H Silber1, R I Jakacki, R L Larsen, J W Goldwein, G Barber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8341214     DOI： 10.1002/mpo.2950210704

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN： 0098-1532


× No keyword cloud information.
  27 in total

1.  Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women.

Authors:  Y Cottin; C Touzery; B Coudert; S Richebourg; M Cohen; M Toubeau; P Louis; J E Wolf; F Brunotte
Journal:  Eur J Nucl Med       Date:  1996-05

Review 2.  Anthracyclines: cardiotoxicity and its prevention.

Authors:  J P Hale; I J Lewis
Journal:  Arch Dis Child       Date:  1994-11       Impact factor: 3.791

3.  Ventricular repolarization time indexes following anthracycline treatment.

Authors:  B Sarubbi; M Orditura; V Ducceschi; F De Vita; L Santangelo; F Ciaramella; G Catalano; A Iacono
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

4.  Dexrazoxane as a cardioprotectant in children receiving anthracyclines.

Authors:  Dana M Sepe; Jill P Ginsberg; Frank M Balis
Journal:  Oncologist       Date:  2010-11-04

5.  Exercise capacity in apparently healthy survivors of cancer.

Authors:  E De Caro; F Fioredda; M G Calevo; A Smeraldi; M Saitta; G Hanau; M Faraci; F Grisolia; G Dini; G Pongiglione; R Haupt
Journal:  Arch Dis Child       Date:  2005-09-27       Impact factor: 3.791

6.  Estrogen but not testosterone preserves myofilament function from doxorubicin-induced cardiotoxicity by reducing oxidative modifications.

Authors:  Chutima Rattanasopa; Jonathan A Kirk; Tepmanas Bupha-Intr; Maria Papadaki; Pieter P de Tombe; Jonggonnee Wattanapermpool
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-11-30       Impact factor: 4.733

Review 7.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 8.  Minimising the long-term adverse effects of childhood leukaemia therapy.

Authors:  Claudia Langebrake; Dirk Reinhardt; Jörg Ritter
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

9.  Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Authors:  Steven E Lipshultz; Rebecca E Scully; Stuart R Lipsitz; Stephen E Sallan; Lewis B Silverman; Tracie L Miller; Elly V Barry; Barbara L Asselin; Uma Athale; Luis A Clavell; Eric Larsen; Albert Moghrabi; Yvan Samson; Bruno Michon; Marshall A Schorin; Harvey J Cohen; Donna S Neuberg; E John Orav; Steven D Colan
Journal:  Lancet Oncol       Date:  2010-09-16       Impact factor: 41.316

Review 10.  Educational paper: decreasing the burden of cardiovascular disease in childhood cancer survivors: an update for the pediatrician.

Authors:  Rejane F Dillenburg; Paul Nathan; Luc Mertens
Journal:  Eur J Pediatr       Date:  2013-01-30       Impact factor: 3.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.